Polymorphisms of glutathione S-transferase μ and θ, MDR1 and VEGF genes as risk factors of bladder cancer: A case-control study

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 5, 2012, Pages 660-665

  Henríquez Hernández, Luis Alberto ^a,d   Navarro, Patricio ^b,d   Luzardo, Octavio P ^a,d   Álvarez León, Eva Elisa ^c,d   Boada, Luis D ^a,d   Zumbado, Manuel ^a,d   Pestano, Jose ^a,d   Suárez, Javier R ^a,d   Chesa, Nicolás ^b,d   Almeida, Maira ^a,d   Valerón, Pilar F ^a,d  

^a UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^b Urology Service   (Spain)

^c Preventive Medicine Service   (Spain)

^d Facultad de Ciencias Farmacéuticas y Bioquímicas   (Spain)

Author keywords

Bladder cancer; Genetic polymorphism; GSTM1; GSTT1; MDR1; Risk factor; VEGF

Indexed keywords

GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; MULTIDRUG RESISTANCE PROTEIN 1; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CASE CONTROL STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SMOKING HABIT; SPAIN; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; GENE FREQUENCY; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; RISK FACTORS; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866762480     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.08.028     Document Type: Article

References (43)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Cohen S.M., Johansson S.L. Epidemiology and etiology of bladder cancer. Urol Clin North Am 1992, 19:421-428.
3. Kim E.J., Jeong P., Quan C., et al. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: Useful determinants for clinical outcome of bladder cancer. Urology 2005, 65:70-75.
4. Garcia-Closas M., Malats N., Real F.X., et al. Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet 2007, 3:e29.
5. Hayes J.D., Flanagan J.U., Jowsey I.R. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005, 45:51-88.
6. El Nouby K.A., Abd El Hameed A.H., Negm O.E., et al. Genetic polymorphism of glutathione-S-transferase (GST-M1 and GST-T1) in schistosomiasis-associated bladder cancer in Egyptian patients. J Egypt Soc Parasitol 2008, 38:991-1006.
7. Pearson W.R., Vorachek W.R., Xu S.J., et al. Identification of class-μ glutathione transferase genes GSTM1-GSTM5 on human chromosome 1p13. Am J Hum Genet 1993, 53:220-233.
8. Rebbeck T.R. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997, 6:733-743.
9. Fost U., Hallier E., Ottenwalder H., et al. Distribution of ethylene oxide in human blood and its implications for biomonitoring. Hum Exp Toxicol 1991, 10:25-31.
10. Engel L.S., Taioli E., Pfeiffer R., et al. Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: A Huge review. Am J Epidemiol 2002, 156:95-109.
11. Abdel-Rahman S.Z., Anwar W.A., Abdel-Aal W.E., et al. GSTM1 and GSTT1 genes are potential risk modifiers for bladder cancer. Cancer Detect Prev 1998, 22:129-138.
12. Salagovic J., Kalina I., Stubna J., et al. Genetic polymorphism of glutathione S-transferases M1 and T1 as a risk factor in lung and bladder cancers. Neoplasma 1998, 45:312-317.
13. Borst P., Elferink R.O. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002, 71:537-592.
14. Schinkel A.H. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997, 8:161-170.
15. Hoffmeyer S., Burk O., von Richter O., et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000, 97:3473-3478.
16. Sauna Z.E., Kimchi-Sarfaty C., Ambudkar S.V., et al. Silent polymorphisms speak: How they affect pharmacogenomics and the treatment of cancer. Cancer Res 2007, 67:9609-9612.
17. Zubor P., Lasabova Z., Hatok J., et al. A polymorphism C3435T of the MDR-1 gene associated with smoking or high body mass index increases the risk of sporadic breast cancer in women. Oncol Rep 2007, 18:211-217.
18. Turgut S., Yaren A., Kursunluoglu R., et al. MDR1 C3435T polymorphism in patients with breast cancer. Arch Med Res 2007, 38:539-544.
19. Rioja Zuazu J., Bandres Elizalde E., Rosell Costa D., et al. Steroid and xenobiotic receptor (SXR), multidrug resistance gene (MDR1) and GSTs, SULTs and CYP polymorphism expression in invasive bladder cancer, analysis of their expression and correlation with other prognostic factors. Acta Urol Esp 2007, 31:1107-1116.
20. Shahbazi M., Fryer A.A., Pravica V., et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002, 13:260-264.
21. Brown L.F., Berse B., Jackman R.W., et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993, 143:1255-1262.
22. Streeter E.H., Harris A.L. Angiogenesis in bladder cancer-prognostic marker and target for future therapy. Surg Oncol 2002, 11:85-100.
23. Yamamori M., Sakaeda T., Nakamura T., et al. Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem Biophys Res Commun 2004, 325:144-150.
24. Kim W.J., Lee H.L., Lee S.C., et al. Polymorphisms of N-acetyltransferase 2, glutathione S-transferase μ and θ genes as risk factors of bladder cancer in relation to asthma and tuberculosis. J Urol 2000, 164:209-213.
25. Henriquez-Hernandez L.A., Murias-Rosales A., Hernandez Gonzalez A., et al. Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: A case-control study. Oncol Rep 2009, 22:1425-1433.
26. Miller M.C., Mohrenweiser H.W., Bell D.A. Genetic variability in susceptibility and response to toxicants. Toxicol Lett 2001, 120:269-280.
27. Awasthi Y.C., Sharma R., Singhal S.S. Human glutathione S-transferases. Int J Biochem 1994, 26:295-308.
28. Pemble S., Schroeder K.R., Spencer S.R., et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994, 300(Pt 1):271-276.
29. Wiencke J.K., Pemble S., Ketterer B., et al. Gene deletion of glutathione S-transferase theta: Correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epidemiol Biomarkers Prev 1995, 4:253-259.
30. Deakin M., Elder J., Hendrickse C., et al. Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: Studies of interactions with GSTM1 in lung, oral, gastric, and colorectal cancers. Carcinogenesis 1996, 17:881-884.
31. Unal M., Tamer L., Ates N.A., et al. Glutathione S-transferase M1, T1, and P1 gene polymorphism in laryngeal squamous cell carcinoma. Am J Otolaryngol 2004, 25:318-322.
32. McGrath M., Michaud D., De Vivo I. Polymorphisms in GSTT1, GSTM1, NAT1, and NAT2 genes and bladder cancer risk in men and women. BMC Cancer 2006, 6:239.
33. Zeng F.F., Liu S.Y., Wei W., et al. Genetic polymorphisms of glutathione S-transferase T1 and bladder cancer risk: A meta-analysis. Clin Exp Med 2010, 10:59-68.
34. Abd El Hameed A.H., Negm O.E., El-Gamal O.M., et al. Genetic polymorphism of glutathione S-transferases M1 and T1 in Egyptian patients with bilharzial bladder cancer. Urol Oncol 2010, 28:296-301.
35. Song D.K., Xing D.L., Zhang L.R., et al. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China. Cancer Detect Prev 2009, 32:416-423.
36. Bell D.A., Taylor J.A., Paulson D.F., et al. Genetic risk and carcinogen exposure: A common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993, 85:1159-1164.
37. Lin H.J., Han C.Y., Bernstein D.A., et al. Ethnic distribution of the glutathione transferase μ 1-1 (GSTM1) null genotype in 1,473 individuals and application to bladder cancer susceptibility. Carcinogenesis 1994, 15:1077-1081.
38. Kim W.J., Kim H., Kim C.H., et al. GSTT1-null genotype is a protective factor against bladder cancer. Urology 2002, 60:913-918.
39. Rouissi K., Ouerhani S., Marrakchi R., et al. Combined effect of smoking and inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 on bladder cancer in a Tunisian population. Cancer Genet Cytogenet 2009, 190:101-107.
40. Tada Y., Wada M., Migita T., et al. Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Int J Cancer 2002, 98:630-635.
41. Prior S.J., Hagberg J.M., Paton C.M., et al. DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption. Am J Physiol Heart Circ Physiol 2006, 290:H1848-H1855.
42. Stevens A., Soden J., Brenchley P.E., et al. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003, 63:812-816.
43. Jin Q., Hemminki K., Enquist K., et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 2005, 11:3647-3653.